Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that ...
Key Points Interested in Surrozen, Inc.? Here are five stocks we like better. Surrozen is advancing a Wnt-based retina ...
This article is Part Two of a three-part community health series presented in partnership with Southern Kentucky Vascular, Somerset.
Yellow light therapy is gaining traction for calming redness and supporting skin repair. Dermatologists explain the benefits, ...
Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, has been awarded an Advanced Research Projects Agency for Health (ARPA-H) contract to develop advanced ...
NEWPORT NEWS, Va. and LONDON, July 22, 2026 /PRNewswire/ -- ivWatch, the IV safety company, today announced that its ...
Chronic insomnia was associated with higher risk for developing mild cognitive impairment and dementia, and individuals with reduced sleep had a higher rate of cognitive decline and more white matter ...
Vasomune Therapeutics, Inc. ("Vasomune"), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that Dr. Harold Kim, Chief Scientific Officer, will ...
T, Boston Children’s Hospital, and Maine’s Jackson Laboratory announced a collaboration Tuesday to develop gene therapies for ...
A $100 million global trial will investigate whether adding a metabolism-targeting therapy to multidomain lifestyle intervention further reduces the risk of cognitive decline in older adults at risk ...
FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...
MONTREAL -- Gene therapy for neovascular age-related macular degeneration (nAMD) achieved stable vision and retinal anatomy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results